Acerus Pharmaceuticals Corporation today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand. Serenity, based in Miami, FL, is a specialty pharmaceutical company focused on developing therapies for diseases associated with voiding disorders and had previously been granted approval by the U.S. Food and Drug Administration (FDA) for its Noctiva™ (desmopressin acetate) nasal spray. Additional details of this transaction can be found in the Company’s filings in the US and Canada.

Acerus will host an investor call to discuss the acquisition of Serenity on March 9, 2022 at 8:30 am Eastern. To access the call live, please dial 416-406-0743 or 1-800-952-5114 and use access code 4028136#. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Wednesday, March 16, 2022 by dialing 905-694-9451 or 1-800-408-3053, using access code:3378123#.

“We are excited to announce the closing of this significant transaction which positions Acerus for faster top line growth and improved long-term performance,” said Edward Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals. “The combined enterprise brings a broader array of offerings to the urology and men’s health markets in North America, leveraging our expanding footprint and strengthening our outlook for years to come.